Intravenous Access Devices; Used to Draw Blood and to Deliver Intravenous Fluids, Drugs, or Blood Transfusions

 

Intravenous Access Devices
Intravenous Access Devices

Intravenous access devices are medical device used to deliver fluids, drugs, and blood products to the patient. These devices are used by physicians for the diagnosis of a patient's condition and for treatment. The devices are also used to test the patient's blood. They may be used for the delivery of a variety of drugs, such as analgesics, medicines for respiratory disorders, and other treatments. The use of intravenous access devices is increasing due to a number of reasons. One of the primary reasons is the increased prevalence of chronic diseases.

Global Intravenous Access Devices Market size was valued at US$ 39,834.8 million in 2019, and is expected to witness a CAGR of 6.7% over the forecast period (2019 – 2027).

Intravenous access devices are used by doctors to deliver medicine to the blood stream through IV (intravenous) route. They can also be used to withdraw blood for testing or diagnosis. Moreover, IV access devices are widely used for blood transfusion, fluid replacement, to deliver medications, and to correct the electrolyte imbalances. They are placed under skin in a skin pocket, on the chest wall or on/under the upper arm, depending on the patient's preference. The catheter is inserted into the central vein, and the port allowing access to the catheter is located just under the skin.

IV access devices, such as IV catheters, IV needles, IV infusion pumps, and catheters, are inserted into veins for people who need frequent access to the bloodstream. These devices are usually placed in one of the larger veins in a chest or neck, so they may remain in place for weeks, months, or longer. IV access devices are used to administer drugs to treat variety of chronic diseases, such as cardiovascular disorders, cancer, diabetes, and more. Thus, there is an increasing demand for Intravenous access devices around the world.

The U.S. Food and Drug Administration (FDA) has granted marketing authorization for the use of the Ellipsys Vascular Access System and the everlinQ endoAVF System to make what’s called an arteriovenous (AV) fistula for patients who need hemodialysis access.

Comments

Post a Comment

Popular posts from this blog

Rising Cancer Cases to boost the Molecular Cytogenetics Market Growth

Image
Molecular Cytogenetics Market Molecular Cytogenetics Market by Products (Kits & Reagents, Instruments, and Software & Services), Technique (Fluorescence in Situ Hybridization, Comparative Genomic Hybridization, Karyotyping, Other Techniques), Application (Cancer, Genetic Disorders, Other Applications), And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030 The global Molecular Cytogenetics Market is estimated to be valued at US$ 4,211.4 million in 2023, and is expected to exhibit a CAGR of 24.5 % over the forecast period, as highlighted in a new report published by Coherent Market Insights. Market Overview: Clinical cytogenetics is the examination of the relation between chromosomal alterations and genetic disorders in human beings. Molecular cytogenetics is an examination of genetic diseases utilizing new techniques and methods that link cytogenetic and molecular t...
Read more

Bispecific Antibodies Are Used As Therapeutic Drugs While Treating Viral Infections, Oncology, And Auto-Immune Diseases

Image
  Bispecific Antibodies Bispecific antibodies are produced through cell fusion or recombinant DNA technologies. Bispecific antibodies are much more specific than monoclonal antibodies. Their applications in tumor immunotherapy are nearly limitless. As of today, seven bispecific antibodies have been approved by the FDA and EMA and over one hundred are in preclinical testing. Bispecific antibodies were initially developed using the quadroma technology. They contain two distinct antigen-binding arms, which enable them to bind to the target antigen while also activating an effector cell, which kills tumor cells. The primary antigen on the surface of the effector cell is called CD3, which is a popular target of immune cells. According to Coherent Market insights the Bispecific Antibodies Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028. Many of these multi specific antibody formats have been developed over the past 30 years. These categories ...
Read more

The rising fungi infections such as athlete’s foot to boost the Antifungal Drugs Market growth

Image
  Antifungal Drugs Market Global Antifungal Drugs Market, by Drug Type (Echinocandins, Polyenes, Allylamines, Azoles, and Others), by Indication (Aspergillosis, Dermatophytosis, Candidiasis, Mucormycosis, and Others), by Dosage Form (Powders, Ointments, Drugs, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2028 The global Antifungal Drugs Market is estimated to be valued at US$ XX million in XXX and is expected to exhibit a CAGR of XX% over the forecast period, as highlighted in a new report published by Coherent Market Insights. Market Overview: There are several kinds of antifungal drugs, out of which in few people can be advised to have over-the-counter (OTC) and few that are prescribed by the physician. Someone who is very weak and has a low immune system and assume to have fungal infection should consult a physician instantly. Yeasts, Molds, and mu...
Read more